SEC Form 4 · accession 0001209191-16-156527
Flexion Therapeutics Inc · FLXN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael D. Clayman
Officer — President and CEO · Director
Period of report
Dec 20, 2016
Accepted (ET)
Dec 22, 2016 · 4:34 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001419600
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $18.56 | Dec 20, 2016 | A | 175,000 | A | — | Dec 19, 2026 | Common Stock | 175,000 | 175,000 | D |
Explanation of responses
- F1Twenty-five percent (25%) of the shares subject to the option shall vest one year after December 20, 2016; thereafter one-forty-eighth (1/48th) of the shares subject to the option shall vest each month following the one year anniversary of December 20, 2016, so that all of the shares subject to the option shall be vested four (4) years after December 20, 2016.